ActHIB vaccine recalled in Japan

Mar 11, 2011

Sanofi Pasteur and Daiichi Sankyo on Friday announced a recall of the ActHIB vaccine in Japan after an "unidentified substance" was found in two syringes.

Daiichi is the Japan marketer of the vaccine manufactured by Sanofi Pasteur, a wing of Paris-headquartered Sanofi-Aventis. The drug is used to prevent bacterial infections causing pneumonia and meningitis.

However, Daiichi told AFP most of the 1.3 million dose shipment had already been used and only a small percentage remained.

A Sanofi Pasteur official told AFP the company was checking how many vaccines had been used.

The official in Tokyo said that the doses "were manufactured on a production line dedicated to the Japanese market".

"They were delivered between September 2010 and late January 2011 but were produced about six months earlier," he added.

Japan's health ministry last week suspended the vaccine along with Pfizer's Prevenar, also used against that can cause and .

The ministry is investigating the recent deaths of six infants who were administered either one or both of the treatments, or in combination with other drugs.

Both Pfizer and Sanofi-Aventis have vouched for the safety of their vaccines and said they are cooperating with the investigation in .

Explore further: Risk of antibiotic overuse in aged care settings

add to favorites email to friend print save as pdf

Related Stories

Japan reports sixth infant death after vaccination

Mar 10, 2011

Japan's health ministry on Thursday reported the death of a sixth infant who recently received vaccinations made by Pfizer or Sanofi-Aventis that have been suspended since last week. ...

Kids' Swine flu shots recalled; not strong enough

Dec 15, 2009

(AP) -- Hundreds of thousands of swine flu shots for children have been recalled because tests indicate the vaccine doses lost some strength, government health officials said Tuesday.

Sanofi to deliver swine flu vaccine in October

Sep 21, 2009

(AP) -- Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France's largest pharmaceutical company said Monday.

Recommended for you

Supermaterial gives rejected drugs a new chance

4 hours ago

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

User comments : 0